More on AGIO

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+13.5% Growth)
- Ratings (7.1 Score)
- Holders
- FDA Archive

Upcoming Events

- Earnings (7/30/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Agios Pharma (NQ:AGIO)
Delayed: 34.16 +1.08 (3.26%)
Prev. Close $33.08  
Open$33.90 
52 Wk High$71.49 
52 Wk Low$33.50 
Day High$34.45 
Day Low$33.50 
P/E N/A  
EPS$-1.18 
Volume2,241,589 

Friends, Peers and Foes (?): FULC NVO (more...)

Jun 18, 2026 04:16 PM Form S-8 AGIOS PHARMACEUTICALS,
Jun 18, 2026 04:13 PM Form 8-K AGIOS PHARMACEUTICALS, For: Jun 18
Jun 16, 2026 04:10 PM Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: Owen Adams Catherine
Jun 16, 2026 04:08 PM Form 4 AGIOS PHARMACEUTICALS, For: Jun 13 Filed by: CAPELLO JEFFREY D
Jun 15, 2026 06:49 AM Agios Pharma (AGIO) PT Raised to $54 at H.C. Wainwright
Jun 13, 2026 09:00 AM Agios presents Phase 3 sickle cell disease trial results at EHA conference
Jun 13, 2026 09:00 AM Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease
Jun 11, 2026 08:38 AM Agios Pharma (AGIO) PT Lowered to $31 at JPMorgan
Jun 1, 2026 05:00 AM Agios licenses blood disorder drug from Oscotec for $25 million upfront
Jun 1, 2026 05:00 AM Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib
View All Articles

Entities mentioned with AGIO

View All Entities